Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
GLP-1 HealthcareThe independent GLP-1 resource
Delivery formats

The GLP-1 shot

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-08-05. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

The GLP-1 shot is a subcutaneous injection — into the layer of fat just under the skin, not into muscle — taken once a week for most products, with a short, fine needle. It is the format every pivotal trial used, and the one the largest published weight-loss results come from. All injectable GLP-1 medications are prescription-only.

Key takeaways

  • Subcutaneous, not intramuscular: it goes into fat, and the needle is short.
  • Weekly for Wegovy, Ozempic, Zepbound and Mounjaro; daily for Saxenda.
  • The injections still produce the largest weight reductions in published trials.
  • The device — pen or vial — changes both the price and, on Medicare, the coverage.

Important limitation: Trial figures come from separate studies with different populations and durations, so differences between them are weaker evidence than a head-to-head comparison would be. Injection technique, sites and rotation are covered on their own page rather than here.

Next action: If needle anxiety is the obstacle, say so to a prescriber before ruling the class out — there are now three approved oral alternatives. If you are starting injections, read injection sites and rotation.

Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration

General education, not medical advice. This page does not teach injection technique — your prescriber and the product's own instructions do that.

What is actually being injected, and where

The needle is short and fine because the medication does not need to reach muscle. It goes into subcutaneous fat, from which it is absorbed slowly — which is part of why most of these products are dosed weekly rather than daily. The abdomen, the front or outer thigh, and the back of the upper arm are the approved areas; the exact spot is rotated each dose. All of that has its own page, with a diagram: injection sites and rotation.

People starting these medications frequently report that the injection was the part they worried about most and found easiest in practice. That is not a promise about your experience — it is a reason to raise needle anxiety with a prescriber rather than treating it as a reason the class is closed to you.

The approved injectable GLP-1 medications

Dosing frequency and approved indication are set by each product’s FDA-approved label and are checkable in DailyMed. Verified 2026-08-05.
ProductMoleculeFrequencyApproved for
WegovySemaglutideWeeklyChronic weight management
OzempicSemaglutideWeeklyType 2 diabetes
ZepboundTirzepatideWeeklyChronic weight management; obstructive sleep apnoea
MounjaroTirzepatideWeeklyType 2 diabetes
SaxendaLiraglutideDailyChronic weight management

The device changes the price, and sometimes the coverage

This is the part almost nobody tells you before you are choosing. The same medication supplied in a different device can carry a different price and a different coverage answer.

The three injection devices and what each one changesThree columns. A multi-dose pen holds several weeks of medication in one device and is dialled to a dose; the Zepbound KwikPen is this form, and it is the one the Medicare GLP-1 Bridge covers. A single-dose pen holds one dose with nothing to set, and is excluded from the Bridge. A vial and syringe requires drawing the dose yourself, and is also excluded. The same medication in a different device can carry a different price and a different coverage answer.mgMulti-dose penSeveral weeks in one device,dialled to a doseZepbound KwikPen is the form theMedicare Bridge coversSingle-dose penOne pen per dose, nothing to setExcluded from the Medicare BridgeVial and syringeYou draw the dose yourselfExcluded from the Medicare Bridge
A multi-dose pen, a single-dose pen and a vial can all contain the same drug. Which one your prescription specifies is not a packaging detail.Device coverage from the Medicare GLP-1 Bridge programme, verified 2026-07-25; self-pay pricing from Eli Lilly, verified 2026-07-25.

Two published examples of what that means in practice:

So “is it covered?” is not quite the right question. The right one is “is this device, of this product, covered?” — and it is worth asking before the prescription is written rather than at the pharmacy counter.

How the shots compare to the tablets

The injections remain the format with the largest published weight-loss results, and tirzepatide the largest of those.

Mean body-weight reduction at the headline dose in each product’s pivotal trial. Separate trials with different populations and durations — not a head-to-head comparison.
ProductWeight reductionmean, at the headline doseTrial
Semaglutide (Wegovy)14.9%STEP 1, NEJM 2021 · N=1,961 · 68 weeks
Tirzepatide (Zepbound)22.5%SURMOUNT-1, NEJM 2022 · N=2,539 · 72 weeks

The injection is not the price of admission to a better drug — it is the format the evidence was built on. The tablets are real, and they are behind on the numbers.

The full comparison, including the three approved tablets, is on the GLP-1 pill page, and every figure with its source sits on our statistics page.

On unusually cheap injectables

  • Every approved injectable here is prescription-only and dispensed by a pharmacy. Vials sold online without a prescription are outside the regulated supply chain.
  • Compounded injectables are not FDA-approved products, and the FDA has documented dosing errors involving differing concentrations and syringe-unit confusion — see reconstitution and product identification.
  • Never take a dose figure from a website. The units on a syringe and the units in a prescription are not always the same thing, and that gap has caused real harm.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved dosage forms, dosing frequency, and administration route for each injectable product named.
  2. Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and dosage form, checkable in Drugs@FDA and the Orange Book.
  3. Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of MedicineSupports: The 14.9% mean body-weight reduction reported for Semaglutide (Wegovy) in STEP 1, NEJM 2021 · N=1,961 · 68 weeks.
  4. Lilly's SURMOUNT-1 Results Published in New England Journal of MedicineEli Lilly (investor release citing NEJM)Supports: The 22.5% mean body-weight reduction reported for Tirzepatide (Zepbound) in SURMOUNT-1, NEJM 2022 · N=2,539 · 72 weeks.
  5. Zepbound coverage and savingsEli Lilly and CompanySupports: Zepbound self-pay pricing by device and dose. Verified 2026-07-25.
  6. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a monthMedicare.gov, Centers for Medicare & Medicaid ServicesSupports: Which injection devices the Medicare GLP-1 Bridge covers, and which it excludes.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.